Fulvestrant: Selective Estrogen Receptor Degrader (SERD)
Fulvestrant is a steroidal antiestrogen that acts as a selective estrogen receptor degrader (SERD). Unlike tamoxifen, which has partial agonist activity, fulvestrant binds to the estrogen receptor (ER), blocks its dimerization, and accelerates its proteasomal degradation, resulting in complete elimination of ER-mediated signaling. This makes fulvestrant the only pure ER antagonist approved for clinical use.
Product Profile
| CAS Number | 129453-61-8 |
|---|---|
| Molecular Formula | C32H47F5O3S |
| Appearance | White to off-white powder |
| Therapeutic Category | Antineoplastic — estrogen receptor degrader |
| Storage | 2–8°C |
Applications
Fulvestrant is approved for the treatment of hormone receptor-positive (HR+), HER2-negative locally advanced or metastatic breast cancer in postmenopausal women, either as monotherapy or in combination with CDK4/6 inhibitors such as palbociclib or ribociclib. It is administered as an intramuscular injection (500 mg), typically into the gluteal muscle. Fulvestrant is increasingly used as first-line endocrine therapy in the metastatic setting and is a key comparator in clinical trials evaluating next-generation oral SERDs.
Why Source from TCS
TCS supplies fulvestrant to pharmaceutical companies across Europe and globally. Flexible order quantities from development samples to commercial volumes. Contact us with your target market and project requirements for a tailored quotation.
FAQ
What information should be included in an inquiry for Fulvestrant 129453-61-8?
A useful inquiry normally includes the product name, target application, estimated quantity, destination market, and any specific documentation or packaging requests.
How is Fulvestrant 129453-61-8 usually evaluated for sourcing?
This product is positioned for pharmaceutical sourcing discussions covering development, pilot, or commercial demand, subject to the buyer confirming application scope, market, and document requirements.
What documentation and commercial points are commonly reviewed before buying Fulvestrant 129453-61-8?
For pharmaceutical API procurement, buyers commonly align on specification review, target market, batch or annual demand, packaging expectations, and the documentation package needed for the project.
Request a Quote
If your team already has a target application, estimated quantity, destination market, or documentation requirements, send those details so the commercial response can be prepared more efficiently.